Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry

Peter Moritz Becher1,2,3, Benedikt Schrage1,2,3, Lina Benson1, Marat Fudim4,5, Carin Corovic Cabrera6,7, Ulf Dahlström8, Giuseppe M.C. Rosano9,10, Ewa A. Jankowska11, Stefan D. Anker12, Lars H. Lund1,13†, and Gianluigi Savarese1,13*†

1Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 2Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; 3German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Berlin, Germany; 4Department of Medicine, Duke University Medical Center, Durham, NC, USA; 5Duke Clinical Research Institute, Durham, NC, USA; 6Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden; 7Department of Cardiology, Södersjukhuset, Stockholm, Sweden; 8Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; 9St George’s Hospital Medical School, London, UK; 10IRCCS San Raffaele Roma, Rome, Italy; 11Department of Heart Diseases, Wroclaw Medical University, and Centre for Heart Diseases, University Hospital, Wroclaw, Poland; 12Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Berlin, Germany; and 13Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden

Received 8 June 2021; revised 11 August 2021; accepted 29 August 2021

Aims
Iron deficiency (ID) is associated with poor prognosis regardless of anaemia. Intravenous iron improves quality of life and outcomes in patients with ID and heart failure (HF) with reduced ejection fraction (HFrEF). In the Swedish HF registry, we assessed (i) frequency and predictors of ID testing; (ii) prevalence and outcomes of ID with/without anaemia; (iii) use of ferric carboxymaltose (FCM) and its predictors in patients with ID.

Methods and results
We used multivariable logistic regressions to assess patient characteristics independently associated with ID testing/FCM use, and Cox regressions to assess risk of outcomes associated with ID. Of 21496 patients with HF and any ejection fraction enrolled in 2017–2018, ID testing was performed in 27%. Of these, 49% had ID and more specifically 36% had ID−/anaemia−, 15% ID−/anaemia+, 29% ID+/anaemia−, and 20% ID+/anaemia+. (48%, 39%, 13%, 30% and 18% in HFrEF, respectively). Risk of recurrent all-cause hospitalizations was higher in patients with ID regardless of anaemia. Of 1959 patients with ID, 19% received FCM (24% in HFrEF). Important independent predictors of ID testing and FCM use were anaemia, higher New York Heart Association class, having HFrEF, and referral to HF specialty care.

Conclusion
In this nationwide HF registry, ID testing occurred in only about a quarter of the patients. Among tested patients, ID was present in one half, but only one in five patients received FCM indicating low adherence to current guidelines on screening and treatment.

*Corresponding author. Department of Medicine, Karolinska Institutet, Heart and Vascular Theme, Karolinska University Hospital, FoU Tema Hjärta Kärl - Norrbacka, S:02, 171 76 Stockholm, Sweden. Tel: +46 764165215, Email: gianluigi.savarese@ki.se
†These authors contributed equally.

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Introduction

Iron deficiency (ID) is highly prevalent in patients with chronic heart failure (HF) and independently associated with high risk of hospitalizations and mortality.1 ID is the main cause of anaemia and is documented in almost 50% of HF patients in Europe.2 In addition, it has been shown to impact prognosis per se, i.e. independently of anaemia and chronic kidney disease, in patients with HF.1,3 Based on these prognostic implications, the 2016 European Society of Cardiology (ESC) guidelines on HF recommend testing for ID in all newly diagnosed patients with HF regardless of haemoglobin levels.4 Treatment with oral iron has not been successful in improving outcomes in HF patients and might be limited by low absorption and high occurrence of gastrointestinal side effects.5 Several randomized controlled trials (RCTs) demonstrated intravenous (IV) iron treatment with ferric carboxymaltose (FCM) improving symptoms, quality of life, functional capacity and reducing risk of HF hospitalizations in patients with symptomatic HF with ejection fraction (EF) <50% and ID regardless of concomitant anaemia.6–9 Therefore, based on the available data, the 2016 ESC guidelines on HF had class Ila, level of evidence A recommendation for FCM in patients with symptomatic HF with reduced EF (HFrEF) and ID in order to improve quality of life, exercise capacity and lessen HF symptoms.4

Despite proven efficacy for optimal guideline-directed medical therapy from RCTs, patients with HFrEF are often undertreated or receive suboptimal doses of HF medications.10 Additionally, limited routine laboratory screening for ID might lead to its underdiagnosis and undertreatment.

Thus, we aimed to (i) assess the likelihood of being tested for ID and identify patient characteristics independently associated with it; (ii) phenotype patients with HF and ID; and (iii) assess the use of FCM and the independent predictors of its use in a real-world cohort of patients with HF across the EF spectrum.

Methods

Study protocol and setting

The Swedish Heart Failure Registry (SwedeHF, www.swedeHF.se) has been described previously.11 For the current analysis, SwedeHF was linked with the National Patient Registry, Statistics Sweden and the Cause of Death Registry. More details on the data sources are reported in the online supplementary Methods S1.

Study population

Patient selection is illustrated in online supplementary Figure S1. For the analyses focusing on ID testing, the study population consisted of all patients enrolled in SwedeHF between 1 January 2017 and 31 December 2018 (as ID biomarkers were collected in SwedeHF during this period but not earlier). For the analyses aiming to characterize ID and to investigate FCM use, registrations with missing data for ferritin/transferrin saturation levels, haemoglobin, and use of FCM were excluded. If the same patient had multiple registrations in SwedeHF, the first one reporting data on the biomarkers of interest was selected. The index date was defined as either the day of the outpatient visit or of hospital discharge linked with the registration in SwedeHF.
Statistical analyses

Missing data

Of 28919 registrations in SwedeHF between 1 January 2017 and 31 December 2018, 22602 (78%) missing values were reported for ferritin, 24037 (83%) for transferrin saturation, 4979 (17%) for haemoglobin, and 1190 (4%) for FCM use. Missing data for variables considered for adjustments in the multivariable models were handled by chained-equations multiple imputation (R package mice). Analyses were performed in 10 imputed datasets and then the estimates were combined by Rubin’s rules. Variables used for the multiple imputation are marked in Table 1 and online supplementary Table S7. The composite outcome of first HF hospitalization/all-cause death was included as the Nelson–Aalen estimator.

Definitions

Patients were considered as tested for ID whether they had a ferritin or transferrin saturation measurement, i.e. missing values were interpreted as lack of testing.

Overall, ID was defined as ferritin <100 μg/L, or ferritin between 100–299 μg/L and transferrin saturation <20%.‡ However, in the analyses aiming to explore the use of FCM, we assumed that patients who were reported as treated with FCM but who did not fulfil the criteria for a diagnosis of ID had normalized ferritin/transferrin saturation levels following a previous treatment with FCM (n = 55). Therefore, these patients were assumed as with ID. Anaemia was defined as haemoglobin <12.0 g/dL in women and <13.0 g/dL in men.‡

Patient characteristics

Baseline characteristics were compared across patients with vs. without ID, also stratifying by anaemia status, i.e. ID−/anaemia−, ID−/anaemia+, ID+/anaemia−, ID+/anaemia+, by Kruskal–Wallis (if continuous) and by chi-squared test (if categorical). Similarly, patient characteristics were compared in patients receiving vs. not receiving ID testing and FCM (online supplementary Table S2).

To evaluate patient characteristics which were independently associated with ID testing and use of FCM, logistic regression models were fitted, with use of ID testing and use of FCM, respectively, as dependent variables and the patient characteristics reported in Figure 1 as covariates. Odds ratio (OR) and 95% confidence interval (CI) were calculated for each potential predictor. In patients receiving FCM, the used doses were visualized by a Kernel density plot.

Outcome analysis

We assessed the associations between ID/anaemia and ferritin/transferrin saturation levels with the following outcomes: a composite of time to first HF hospitalization or all-cause death, time to first HF hospitalization, time to all-cause death, time to first all-cause hospitalization, time to first HF outpatient visit as well as the total number of HF hospitalizations, all-cause hospitalizations and HF outpatient visits. Data were censored on 31 December 2018 or at death (if not defined as an event) or emigration from Sweden.

To investigate the association between ID/anaemia, ferritin/transferrin saturation levels and outcomes, cumulative incidence curves were fitted. Multivariable Cox regression models for time to event analyses and negative binomial regressions (including the log of time as an offset in the model) for repeated event analyses were performed to provide adjusted estimates (variables used for the adjustment are marked in Table 1 and online supplementary Table S7). The proportional hazard assumption was verified by Schoenfeld residuals and met.

All statistical analyses were performed by R 4.0.2 and the R code for data handling and statistical analyses can be found at https://github.com/KIHeartFailure/iron. A two-sided P-value <0.05 was considered as statistically significant.

Results

Iron deficiency testing and predictors of iron deficiency testing use

Between 1 January 2017 and 31 December 2018, there were 21496 patients registered in SwedeHF and 5708 (27%) were tested for ID [i.e. measurement of only ferritin (1472, 7%), of only transferrin saturation (221, 1%), or of both ferritin and transferrin saturation (4015, 19%)] (Graphical Abstract, Table 1, online supplementary Table S3). Of these, 2691 (57%) had HFrEF, 1113 (24%) HF with mildly reduced EF (HFrEF), and 907 (19%) HF with preserved EF (HFrEF). ID testing was performed in 32% of patients with anaemia and 28% of those without anaemia, with similar differences in testing according to anaemia status across the EF spectrum (Graphical Abstract).

Of all tested variables, key patient characteristics independently associated with higher likelihood of ID testing were enrolment in SwedeHF registry as an outpatient, having HFrEF vs. HFrEF vs. HFrEF, more severe/symptomatic HF [i.e. higher New York Heart Association (NYHA) class, use of diuretics and mineralocorticoid receptor antagonists (MRAs)], use of beta-blockers, anaemia, male sex, longer HF duration, follow-up referral to HF nurse-led clinic, referral to follow-up in primary care, and being registered in SwedeHF in 2018 vs. 2017 (Figure 7). Geographical distribution of ID testing in Sweden is shown in online supplementary Figure S2 and Table S4.

Characterization of iron deficiency

Prevalence

Of 3757 patients with available data on ferritin, transferrin saturation, haemoglobin and FCM, 36% had neither ID nor anaemia (ID−/anaemia−), 29% had only ID (ID+/anaemia−), 15% had only anaemia (ID−/anaemia+), and 20% had both ID and anaemia (ID+/anaemia+) (Graphical Abstract, Table 2, online supplementary Table S5). In patients with HFrEF, 27% had ID−/anaemia−, 27% had ID+/anaemia−, 17% had ID−/anaemia+, and 29% had ID+/anaemia+. Corresponding estimates in patients with HFrEF were 34% for ID−/anaemia−, 28% for ID+/anaemia−, 16% for ID−/anaemia+, and 22% for ID+/anaemia+. In HFrEF, 39% had ID−/anaemia−, 30% ID+/anaemia−, 13% ID−/anaemia+, and 18% ID+/anaemia+ (Graphical Abstract, Table 2, online supplementary Tables S6–S8). Prevalence of ID regardless of anaemia was 49% in the overall population, 56% in HFrEF, 50% in HFrEF, and 48% in HFrEF.
Regardless of the EF phenotype, patients with ID+/anaemia+ and ID+/anaemia− were more likely older, more symptomatic for HF (i.e., higher NYHA class, higher NT-proBNP levels, use of diuretics), and more likely to have ischaemic heart disease (Table 2, online supplementary Table S5).

Patients with ID+/anaemia+ were more likely to have HfPeF, more symptomatic/severe HF (i.e., higher NYHA class, higher NT-proBNP, use of diuretics and nitrates) and higher comorbidity burden (ischaemic heart disease, diabetes, hypertension, prior
stroke, chronic obstructive pulmonary disease, valvular disease) and to be followed up in primary care compared with those with ID−/anaemia− (Table 2, online supplementary Tables S5 and S6). Patients with ID−/anaemia+ showed a profile which resembled more ID+/anaemia+, whereas ID+/anaemia− resembled more ID−/anaemia−. Use of HF treatments (i.e. MRA and device therapy) was highest in patients with ID+/anaemia− and ID−/anaemia−, who also were more likely to have preserved renal function and HFREF (online supplementary Table S8). Overall, patient characteristics according to ID/anaemia were consistent across the EF spectrum (online supplementary Tables S6–S8).

**Outcome analysis according to iron deficiency and anaemia status**

Over a median (interquartile range) follow-up of 19.4 (0.1–35.9) months, in time to event analyses and compared with ID−/anaemia−, ID+/anaemia+ was associated with the higher risk of all the outcomes (all-cause death orHF hospitalization: adjusted hazard ratio (HR) 1.48 (95% CI 1.25–1.74), P < 0.001; all-cause death: adjusted HR 1.55 (95% CI 1.23–1.95), P < 0.001; first HF hospitalization: adjusted HR 1.38 (95% CI 1.14–1.67), P = 0.001; and first all-cause hospitalization: adjusted HR 1.39 (95% CI 1.23–1.58), P < 0.001) except for first HF visit (whose risk was similar across the study groups); ID−/anaemia+ was associated with higher risk of all-cause death/first HF hospitalization [adjusted HR 1.23 (95% CI 1.03–1.48), P = 0.024] and all-cause death [adjusted HR 1.41 (95% CI 1.10–1.82), P = 0.008]; there were no statistically significant differences in risk of outcomes with ID+/anaemia− (Figure 2, Table 3, online supplementary Figure S3).

In the recurrent event analyses, ID+/anaemia+ was associated with statistically significantly higher risk of all-cause and HF hospitalizations [adjusted incident rate ratio (IRR) 1.43 (95% CI 1.25–1.63), P < 0.001; and adjusted IRR 1.37 (95% CI 1.10–1.72), P = 0.005], whereas ID+/anaemia− [adjusted IRR 1.17 (95% CI 1.04–1.31), P = 0.008] and ID−/anaemia+ [adjusted IRR 1.30 (95% CI 1.12–1.50), P < 0.001] with higher risk of all-cause hospitalizations compared with ID−/anaemia− (Table 3).

Of note, when included in the same Cox regression (including also the covariates reported in Table 1), transferrin saturation <20% vs. ≥20% was significantly associated with higher risk of all the investigated outcomes (i.e. all-cause death/first HF hospitalization, all-cause death, first and recurrent HF hospitalizations, first and recurrent all-cause hospitalizations, and first recurrent HF visits), whereas ferritin <100 vs. ≥100 μg/L was only associated with higher risk of recurrent HF hospitalizations and recurrent all-cause hospitalizations (online supplementary Table S9).

**Characterizing ferric carboxymaltose use**

**Ferric carboxymaltose use**

In the overall HF cohort with ID, 19% of patients received FCM treatment and of these 52% had anaemia (Graphical Abstract, online...
While corresponding proportions were patients with ID, 24% received FCM and 47% of them had anaemia, and 15% and 80% in HFpEF (Graphical Abstract, online supplementary Tables S2 and S10–S12). Detailed information on geographical distribution of FCM use in Sweden is shown in online supplementary Figure S2 and Table S13.

**Table 2 Baseline characteristics in the study population stratified according to iron deficiency/anaemia status**

| Variable                          | Missing | ID−/A− (%) | ID+/A− (%) | ID+/A+ (%) | P-value |
|-----------------------------------|---------|------------|------------|------------|---------|
| n (%)                             | 0.0     | 1351 (36)  | 541 (15)   | 1100 (29)  | 0.001   |
| Male sex, n (%)                   | 0.0     | 985 (27.9) | 444 (82.1) | 654 (95.9) | <0.001  |
| Age (years), median [IQR]         | 0.0     | 72.0 [64.0–78.5] | 77.0 [71.0–83.0] | 73.0 [63.0–79.2] | <0.001  |
| Outpatient location, n (%)        | 0.0     | 1299 (96.2) | 471 (8.7)  | 1047 (95.2) | <0.001  |
| HF subtype, n (%)                 | 15.0    |            |            |            |         |
| HFpEF                             |         | 749 (65.0) | 249 (54.0) | 571 (61.8) | 0.334   |
| HfmrEF                            |         | 249 (21.6) | 117 (25.4) | 202 (21.9) | 0.159   |
| NYHA class, n (%)                 | 16.2    |            |            |            | <0.001  |
| I                                 |         | 153 (13.1) | 36 (8.4)   | 86 (9.1)   | 0.031   |
| II                                |         | 599 (51.2) | 191 (44.3) | 468 (49.3) | 0.225   |
| III                               |         | 406 (34.7) | 200 (46.4) | 390 (41.1) | 0.327   |
| IV                                |         | 12 (1.0)   | 4 (0.9)    | 6 (0.6)    | 0.13    |
| Systolic blood pressure (mmHg), median [IQR] | 2.0 | 125.0 [110.0–140.0] | 121.0 [110.0–135.0] | 125.0 [111.0–140.0] | 0.005 |
| Diastolic blood pressure (mmHg), median [IQR] | 1.8 | 73.0 [65.0–79.5] | 73.0 [65.0–80.0] | 70.0 [60.0–80.0] | <0.001 |
| Heart rate (bpm), median [IQR]    | 2.4     | 69.0 [60.0–79.0] | 70.0 [61.0–80.0] | 72.0 [64.0–82.0] | <0.001 |
| BMI (kg/m²)                       | 50.9    | 27.2 [24.6–30.8] | 25.0 [22.5–27.7] | 27.3 [24.1–31.1] | 0.026   |
| eGFR (CKD-EPI) (ml/min/1.73 m²), median [IQR] | 0.5 | 68.0 [52.1–82.6] | 52.7 [37.9–72.3] | 65.5 [48.8–83.2] | 0.052   |
| NT-proBNP (pg/mL), median [IQR]   | 10.0    | 1293.5 [527.2–2668.0] | 2890.0 [1332.0–6008.0] | 1590.0 [596.0–3471.0] | <0.001 |
| Smoking, former/current, n (%)    | 2.1     | 574 (58.0) | 213 (56.6) | 489 (60.1) | 0.432   |
| Diabetes, n (%)                   | 0.0     | 294 (21.8) | 159 (29.4) | 307 (27.9) | 0.267   |
| Atrial fibrillation/flutter, n (%)| 0.0     | 744 (55.1) | 322 (59.5) | 560 (50.9) | 0.457   |
| Ischaemic heart disease, n (%)    | 0.0     | 622 (46.8) | 328 (60.6) | 572 (52.0) | 0.469   |
| Hypertension, n (%)               | 0.0     | 855 (63.3) | 391 (72.3) | 739 (67.2) | 0.607   |
| Heart failure, n (%)              | 0.0     | 211 (15.6) | 130 (24.0) | 176 (16.0) | 0.204   |
| COPD, n (%)                       | 0.0     | 126 (9.3)  | 71 (13.3)  | 151 (13.7) | 0.141   |
| RAS/ARN, n (%)                    | 0.2     | 126 (94.0) | 474 (87.6) | 995 (90.8) | 0.638   |
| Beta-blocker, n (%)               | 0.1     | 1261 (93.3) | 487 (90.0) | 1030 (93.9) | 0.678   |
| MRA, n (%)                        | 0.1     | 743 (55.0) | 242 (44.7) | 517 (47.1) | 0.358   |
| Device therapy (CRT/ICD), n (%)   | 0.4     | 248 (18.5) | 79 (14.7)  | 180 (16.5) | 0.65    |
| Diuretic, n (%)                   | 0.2     | 946 (70.0) | 444 (82.1) | 787 (71.8) | 0.639   |
| Statin, n (%)                     | 0.1     | 691 (51.2) | 303 (56.0) | 583 (53.1) | 0.449   |
| Nitrates, n (%)                   | 0.2     | 63 (47.0)  | 69 (12.8)  | 112 (10.2) | 0.204   |
| Follow-up referral HF nurse-led clinic, n (%) | 2.8 | 1188 (89.3) | 428 (82.9) | 971 (89.7) | 0.605   |
| Follow-up referral specialty, n (%)| 1.4     |            |            |            | <0.001  |
| Hospital                          |         | 1106 (82.7) | 406 (76.3) | 865 (79.4) | 0.539   |
| Primary care                      |         | 225 (16.8) | 117 (22.0) | 215 (19.7) | 0.192   |
| Other                             |         | 7 (0.5)    | 9 (1.7)    | 10 (0.9)   | 0.14    |
| Education, n (%)                  | 1.7     |            |            |            | 0.006   |
| Compulsory school                 |         | 415 (31.3) | 213 (39.7) | 377 (34.9) | 0.290   |
| Secondary school                  |         | 619 (46.7) | 223 (41.6) | 493 (45.6) | 0.320   |
| University                        |         | 292 (22.0) | 100 (18.7) | 210 (19.4) | 0.143   |

A, anaemia; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart failure with mildly reduced ejection fraction; HfmrEF, heart failure with preserved ejection fraction; HFHF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; ID, iron deficiency; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RASI, renin–angiotensin system inhibitor.

*Indicates the multiple imputation models and logistic/Cox regressions.

Supplementary Table S2. Most patients received 1000 mg of FCM (online supplementary Figure S4). In particular, of 963 HFrEF patients with ID, 24% received FCM and 47% of them had anaemia, while corresponding proportions were 12% and 71% in HfmrEF, and 15% and 80% in HFpEF (Graphical Abstract, online supplementary Tables S2 and S10–S12). Detailed information on geographical distribution of FCM use in Sweden is shown in online supplementary Figure S2 and Table S13.

**Baseline characteristics and independent predictors of ferric carboxymaltose use**

Patients receiving FCM vs. non receiving FCM were less likely encountered in outpatient care and more likely to have anaemia, diabetes, ischaemic heart disease, HFrEF, and more severe HF (i.e. higher NYHA class, higher NT-proBNP levels and lower blood pressure) (online supplementary Table S2). They were also more likely to receive MRAs, diuretics and device therapies.
| Outcome                        | HR (95% CI) |
|-------------------------------|-------------|
| All-cause death/              |             |
| First HF hospitalization      |             |
| Crude HR: ID+/A+              | 2.46 (2.12-2.85) |
| Adj. HR: ID+/A+               | 1.48 (1.25-1.74) |
| Crude HR: ID+/A-              | 1.90 (1.60-2.26) |
| Adj. HR: ID+/A-               | 1.23 (1.03-1.48) |
| Crude HR: ID+/A+              | 1.23 (1.06-1.44) |
| Adj. HR: ID+/A+               | 1.12 (0.96-1.31) |
| Reference: ID-/A+             | Reference   |

| All-cause death               |             |
| Crude HR: ID+/A+              | 3.05 (2.47-3.76) |
| Adj. HR: ID+/A+               | 1.55 (1.23-1.95) |
| Crude HR: ID+/A-              | 2.68 (2.12-3.38) |
| Adj. HR: ID+/A-               | 1.41 (1.10-1.82) |
| Crude HR: ID+/A+              | 1.10 (0.87-1.40) |
| Adj. HR: ID+/A+               | 0.96 (0.75-1.22) |
| Reference: ID+/A-             | Reference   |

| First HF hospitalization      |             |
| Crude HR: ID+/A+              | 2.17 (1.83-2.58) |
| Adj. HR: ID+/A+               | 1.38 (1.14-1.67) |
| Crude HR: ID+/A-              | 1.65 (1.35-2.02) |
| Adj. HR: ID+/A-               | 1.11 (0.89-1.37) |
| Crude HR: ID+/A+              | 1.24 (1.05-1.48) |
| Adj. HR: ID+/A+               | 1.14 (0.95-1.36) |
| Reference: ID-/A-             | Reference   |

| First all-cause hospitalization |             |
| Crude HR: ID+/A+              | 2.10 (1.88-2.35) |
| Adj. HR: ID+/A+               | 1.39 (1.23-1.58) |
| Crude HR: ID+/A-              | 1.60 (1.40-1.82) |
| Adj. HR: ID+/A-               | 1.11 (0.97-1.28) |
| Crude HR: ID+/A+              | 1.13 (1.02-1.27) |
| Adj. HR: ID+/A+               | 1.04 (0.92-1.16) |
| Reference: ID-/A-             | Reference   |

| First HF visit                |             |
| Crude HR: ID+/A+              | 1.00 (0.89-1.12) |
| Adj. HR: ID+/A+               | 1.05 (0.92-1.19) |
| Crude HR: ID+/A+              | 1.05 (0.92-1.19) |
| Adj. HR: ID+/A+               | 1.05 (0.92-1.20) |
| Crude HR: ID+/A-              | 1.03 (0.93-1.14) |
| Adj. HR: ID+/A-               | 1.06 (0.96-1.17) |
| Reference: ID-/A-             | Reference   |

**Figure 2** Outcome analysis according to iron deficiency/anaemia (ID/A) status. CI, confidence interval; HF, heart failure; HR, hazard ratio.
Anaemia were associated with the highest risk of morbidity and mortality, with anaemia being more severe HF and higher burden of comorbidities including diabetes and heart failure.

Table 3: Outcome analyses according to iron deficiency/anaemia status

| Outcome | ID−/A− | ID−/A+ | ID+/A− | ID+/A+ |
|---------|--------|--------|--------|--------|
| All-cause death/first HF hospitalization | | | | |
| Event rates (+1000 pt-years) | 160 (143–178) | 312 (272–356) | 198 (176–221) | 405 (365–448) |
| Crude HR (95% CI), P-value | Reference | 1.90 (1.60–2.26), <0.001 | 1.23 (1.06–1.44), 0.008 | 2.46 (2.12–2.85), <0.001 |
| Adjusted HR (95% CI), P-value | Reference | 1.23 (1.03–1.48), 0.024 | 1.12 (0.96–1.31), 0.160 | 1.48 (1.25–1.74), <0.001 |
| All-cause death | | | | |
| Event rates (+1000 pt-years) | 62 (53–74) | 166 (140–197) | 69 (57–82) | 190 (166–217) |
| Crude HR (95% CI), P-value | Reference | 2.68 (2.12–3.38), <0.001 | 1.10 (0.87–1.40), 0.433 | 3.05 (2.47–3.76), <0.001 |
| Adjusted HR (95% CI), P-value | Reference | 1.41 (1.10–1.82), 0.008 | 0.96 (0.75–1.22), 0.727 | 1.55 (1.23–1.95), <0.001 |
| First HF hospitalization | | | | |
| Event rates (+1000 pt-years) | 125 (110–141) | 214 (181–251) | 156 (137–176) | 283 (250–319) |
| Crude HR (95% CI), P-value | Reference | 1.65 (1.35–2.02), <0.001 | 1.24 (1.05–1.48), 0.014 | 2.17 (1.83–2.58), <0.001 |
| Adjusted HR (95% CI), P-value | Reference | 1.11 (0.89–1.37), 0.350 | 1.14 (0.95–1.36), 0.163 | 1.38 (1.14–1.67), 0.001 |
| First all-cause hospitalization | | | | |
| Event rates (+1000 pt-years) | 224 (205–244) | 339 (300–381) | 292 (268–317) | 423 (386–461) |
| Crude IRR (95% CI), P-value | Reference | 1.72 (1.34–2.22), <0.001 | 1.30 (1.06–1.60), 0.012 | 2.12 (1.70–2.65), <0.001 |
| Adjusted IRR (95% CI), P-value | Reference | 0.98 (0.76–1.25), 0.850 | 1.16 (0.95–1.42), 0.141 | 1.37 (1.10–1.72), 0.005 |
| All-cause hospitalizations | | | | |
| Event rates (+1000 pt-years) | 419 (388–452) | 701 (629–778) | 477 (439–517) | 943 (867–1023) |
| Crude HR (95% CI), P-value | Reference | 1.60 (1.40–1.82), <0.001 | 1.13 (1.02–1.27), 0.026 | 2.10 (1.88–2.35), <0.001 |
| Adjusted HR (95% CI), P-value | Reference | 1.11 (0.97–1.28), 0.128 | 1.04 (0.92–1.16), 0.551 | 1.39 (1.23–1.58), <0.001 |
| First HF visit | | | | |
| Event rates (+1000 pt-years) | 677 (644–712) | 1228 (1153–1306) | 871 (829–915) | 1438 (1370–1508) |
| Crude IRR (95% CI), P-value | Reference | 1.98 (1.71–2.29), <0.001 | 1.30 (1.15–1.46), <0.001 | 2.34 (2.06–2.66), <0.001 |
| Adjusted IRR (95% CI), P-value | Reference | 1.30 (1.12–1.50), <0.001 | 1.17 (1.04–1.31), 0.008 | 1.43 (1.25–1.63), <0.001 |
| HF visits | | | | |
| Event rates (+1000 pt-years) | 710 (664–759) | 753 (674–839) | 721 (669–777) | 698 (635–766) |
| Crude HR (95% CI), P-value | Reference | 1.05 (0.92–1.19), 0.463 | 1.03 (0.93–1.14), 0.525 | 1.00 (0.89–1.12), 0.992 |
| Adjusted HR (95% CI), P-value | Reference | 1.05 (0.92–1.20), 0.473 | 1.06 (0.96–1.17), 0.278 | 1.05 (0.92–1.19), 0.480 |
| Crude IRR (95% CI), P-value | Reference | 1.09 (0.96–1.25), 0.183 | 1.06 (0.95–1.17), 0.298 | 1.10 (0.98–1.24), 0.098 |
| Adjusted IRR (95% CI), P-value | Reference | 1.04 (0.91–1.18), 0.567 | 1.08 (0.98–1.19), 0.110 | 1.04 (0.93–1.17), 0.495 |

A, anaemia; CI, confidence interval; HF, heart failure; HR, hazard ratio; ID, iron deficiency; IRR, incident rate ratio; pt, patient.

Of all the variables which were tested in our multivariable model, patient characteristics independently associated with FCM use were more severe HF (i.e. higher NYHA class and MRA use), HFrEF vs. HFmrEF vs. HfP EF, lower haemoglobin levels, diabetes, and follow-up to specialty care (Figure 1). FCM use did not significantly differ in 2017 vs. 2018 (P = 0.067) (Figure 1).

Discussion

This analysis from SwedeHF demonstrated six major findings: (i) testing for diagnosing ID was performed only in approximately a quarter of our HF population; (ii) key patient characteristics associated with ID testing were anaemia, HFrEF, more severe HF, and more specialized follow-up; (iii) ID was highly prevalent, i.e. observed in half of the population; (iv) comorbid ID and anaemia were associated with the highest risk of morbidity and mortality, with ID alone associated with higher risk of all-cause hospitalizations; (v) only one out of five patients with an indication received FCM treatment; and (vi) patients receiving FCM had more severe HF and higher burden of comorbidities including anaemia.

Iron deficiency testing and burden of iron deficiency in real-world heart failure

Previous studies report the prevalence of ID in HF ranging between 35% and 43%.12,13 Consistently, routine evaluation of iron status in HF is recommended by international guidelines.4

We observed that ID testing was performed in only about a quarter of the population. Anaemia was among the strongest predictors of ID testing, with the likelihood of being tested increasing with lower haemoglobin levels, which might suggest a diagnostic work-up for anaemia rather than screening for ID in HF, which is both prognostic and treatable regardless of anaemia.14

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Consistent with other studies, half of our HF population had ID.\(^5\) We found that HF patients who were tested for ID had more symptomatic HF, which might highlight physicians’ efforts to identify non-cardiac causes of dyspnoea and, potentially, to consider treatment of ID when diagnosed. Patients who were tested for ID were more likely to receive HF treatments, which might suggest that those receiving optimal care in terms of HF treatments are also more likely tested for ID as part of the HF management. Consistently, ID testing was associated with referral to HF nurse-led clinic, which might be explained by an enhanced multidisciplinary care in these patients and by HF nurse teams administering IV iron treatment as part of the optimization of HF therapy.\(^6\) ID testing was more frequent in an outpatient setting, which is counterintuitive since ID might be more easily treated during a hospitalization for HF when IV iron treatment might further help in the amelioration of HF symptoms. The likelihood of being tested for ID was higher in HFrEF although recommended by guidelines in HF regardless of EF. This might indicate that physicians might be more likely to search for ID in a setting where there is good evidence and clear recommendation for treatment, i.e. FCM use in HFrEF.\(^4\) However, undertesting is not only observed for ID in HF, with natriuretic peptide assessment still limitedly implemented although there is clear evidence for its diagnostic and prognostic role.\(^17\)

In our study, we explored the different profiles of patients with vs. without ID, also stratifying by anaemia status. Importantly, a significant proportion of our population had ID without anaemia (29%), which is consistent with findings from previous studies (32%).\(^4\) Patients with ID+/anaemia− had a profile overall resembling more ID+/anaemia− than ID+/anaemia+, and in terms of comorbidity burden and HF severity. In accordance with previous studies, we found that patients with ID+/anaemia− were more likely female, had higher NT-proBNP levels, higher NYHA class, and slightly impaired renal function compared with patients with ID−/anaemia−, whereas highest NT-proBNP levels and NYHA class were observed in patients with anaemia regardless of ID, who also reported the highest comorbidity burden.\(^1,2,18\) Consistently with previous studies, we observed the most impaired renal function in patients with anaemia with and without ID,\(^2,18\) with anaemia having been shown in other analyses as an additional marker of severity rather than a causal factor of chronic kidney disease.\(^23\)

Consistent with these differences in patient profiles and in agreement with previous reports, we could show that patients with concomitant anaemia and ID were at highest risk of mortality.\(^1,24\) However, those analyses highlighted higher risk of all-cause death in patients with ID without anaemia and no prognostic role of anaemia in absence of ID, whereas we observed higher mortality with anaemia without ID and no significantly increased risk of all-cause death in those with ID without anaemia.\(^1,24\) These discrepancies might be at least partially explained by selection bias and residual confounding, with patients with anaemia and more advanced HF being more likely to be tested and thus included in the current study compared with those with severe HF but without anaemia. Even if there was a bias in our analysis, we could provide an overall picture of ID/anaemia as appears according to the current practice in ID testing in real-world HF. We also showed that the risk of recurrent all-cause hospitalizations was higher in patients with ID regardless of concomitant anaemia, with similar HRs for recurrent HF hospitalizations although in absence of statistically significance likely due to sample size issues. The finding of increased risk of hospitalizations with ID appears consistent with RCTs showing reductions in cardiovascular/HF hospitalizations without an effect on mortality alone with FCM.\(^8,9\)

Finally, we observed that transferrin saturation <20% vs. ≥20% was associated with higher risk of all investigated outcomes after adjustments for ferritin levels and other patient characteristics, whereas ferritin <100 μg/L vs. ≥100 μg/L was only associated with higher risk of recurrent all-cause hospitalizations and recurrent HF hospitalizations after adjustment for transferrin saturation and other potential confounders. These findings are consistent with previous studies suggesting a worse prognostic role for transferrin saturation <20% regardless of ferritin levels, anaemia, and other comorbidities.\(^24,25\) Consistently, it has been previously shown that an impaired iron transport (transferrin saturation <20%) but not impaired iron storage (ferritin <100 μg/L) is independently associated with increased sympathetic activation, i.e. elevated norepinephrine levels, in patients with chronic HF.\(^26\)

### Use of ferric carboxymaltose in real-world care

Pooled data from several RCTs have highlighted a role for IV iron in reducing the combined risk of all-cause death or cardiovascular hospitalization, alleviating HF symptoms, and improving exercise capacity and quality of life.\(^8\) Accordingly, the European and US guidelines recommend that IV iron treatment should be offered to symptomatic patients with HFrEF and ID, but the class of recommendation varies between IIa and IIb.\(^4,27\) Additionally, beyond impacting outcomes, quality of life and improving symptoms, data from the AFFIRM-AHF trial have shown that treatment with FCM is also highly cost-effective in patients with ID stabilized after a hospitalization for acute HF,\(^18\) which was mainly explained by the reduction in HF hospitalizations.

There are currently scarce data on the use of IV iron treatment in real-world HF, with few studies suggesting limited implementation, i.e. ranging between 3% and 24%.\(^15\) We observed that 19% of our HF population with ID received FCM treatment, more than half of them with concomitant anaemia, and, as expected, use was highest in HFrEF. These data highlight that despite current guideline recommendation, FCM is still underutilized in HF patients in clinical practice. This is also in line with the observed underutilization of several guideline-recommended medications, device therapies and multidisciplinary strategies in HF.\(^16,29−31\) In our analysis, key patient characteristics independently associated with FCM use were more severe HF and a higher burden of comorbidities including anaemia, which might highlight the attempt to reduce symptoms by treating ID. While ID testing use was more common in an outpatient setting, FCM was more likely used in inpatients, which might indicate that although patients are diagnosed with ID, treatment might not occur after ID testing but might be delayed in some cases until an urgent hospitalization due to clinical inertia or...
prioritization or logistical issues. Anaemia was not only a major determinant for ID screening, but was also associated with FCM administration. This finding underlines the commonly held belief that treating ID is only needed in the presence or on the basis of the degree of anaemia.

Limitations

Our study has several limitations that should be acknowledged. First, we defined missing values for ID biomarkers as lack of testing. However, some patients might have been tested for ferritin/transferrin saturation levels, but the values could not have been entered in the registry. Second, our data suggest that testing was performed for suspect of anaemia rather than of ID, which might have led to overestimate the prevalence of anaemia and underestimate that of ID. Third, repeated assessment of ferritin/transferrin saturation levels and of FCM use was not available, which prevented to capture later use of FCM during follow-up and to investigate the longitudinal relationship between ferritin/transferrin saturation levels, ID status and treatment with FCM. Forth, in SwedeHF there is no information regarding the indications underlying the prescription of specific medications. Therefore, we could only assume that patients receiving FCM but with normal ferritin/transferrin saturation levels had ID which had been successfully treated with FCM. Finally, SwedeHF is a nationwide continuous registry, but it does not have complete coverage and enrols primarily patients in secondary care. Therefore, selection bias may still represent a limitation, with better treated patients enrolled in our registry, which could have led to overestimate FCM use.

Conclusion

In this nationwide HF registry, ID testing was performed in only about a quarter of the population. ID was highly prevalent, i.e. half of the study cohort, but only one in five patients with ID received FCM treatment. A major determinant for limited testing and treatment of ID was the lack of concomitant anaemia. Consistently, ID testing rates were higher in patients with vs. without anaemia. This highlights the misconception that ID is a treatment target only in the presence of anaemia. Our data indicate low adherence to current guidelines in terms of screening for and treatment of ID in HF patients. Appropriate diagnostic and interventional strategies are needed to improve ID management and overall HF care.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Funding

This analysis was supported by Vifor Pharma (grant to Dr. Savarese). The funding sources had no role in the design of this study, execution, analyses, interpretation of the data, or decision to submit results.

Conflict of interest: G.S reports grants and personal fees from AstraZeneca, Vifor, grants and non-financial support from Boehringer Ingelheim, personal fees from Societá Prodotto Antibiotici, Roche, Servier; GENESIS, Cytokinetics, Medtronic, and grants from Novartis, Boston Scientific, PHARMACOSMOS, outside the submitted work. P.M.B. received funding from the German Research Foundation, outside the submitted work. B.S. received funding from the German Research Foundation and the Else Kröner-Fresenius-Stiftung, and speaker fees from AstraZeneca, outside the submitted work. M.F. received funding from the NHLBI K23HL151744 from the National Heart, Lung, and Blood Institute (NHLBI), the American Heart Association grant No 20IPA3531095S, Mario Family Award, Duke Chair’s Award, Translating Duke Health Award, Bayer and BTG Specialty Pharmaceuticals, and consulting fees from AxonTherapies, Bodyport, CVRx, Daxor, Edwards LifeSciences, NXT Biomedical, Zoll, Viscardia, outside the submitted work. U.D. reports grants from Boehringer Ingelheim, AstraZeneca, Pfizer, Vifor, Boston Scientific and Roche Diagnostics; consulting fees from Amgen and Novartis, and speaker fees from AstraZeneca, outside the submitted work. L.H.L. reports personal fees from Merck, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia, Sanofi, Lexicon, grants and personal fees from Vifor-Fresenius, AstraZeneca, Relypsa, Boehringer Ingelheim, Novartis, grants from Boston Scientific, outside the submitted work. E.A.J. reports grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda, Gededon Richter, outside the submitted work. S.D.A. reports receiving fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Cordio, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma, and grant support from Abbott and Vifor Pharma, outside the submitted work. The other authors have nothing to disclose.

References

1. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentstiel P, Torrens A, Polonoski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575–582.e3.
2. Jankowska EA, Tkaczysszn M, Drozd M, Ponikowski P. Monitoring of iron status in patients with heart failure. Eur Hear J Suppl 2019;21(Suppl M):M32–M35.
3. Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellos M, Merono O, Ribas N, Ruiz S, Gomez M, Verdu JM, Brugueria J. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail 2013;15:1164–1172.
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Cowie MR, Dargie HJ, Drexler H, Erdmann E, Follath F,FM, Granger CB, Hamm CW, Jankowska EA, Komajda M, Le Heuzey JY, Linde C, Mardell E, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
5. Lewis GD, Malhostra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E. NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 2017;317:1958–1966.

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Iron deficiency and heart failure

6. Anker SD, Comin-Colet J, Filipatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Basinak W, Niegoska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448.

7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Erü G, Komajda M, Marcev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filipatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–668.

8. Jankowska EA, Tzacszymszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Basinak W, Filipatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016;18:786–795.

9. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filipatos G, Gohring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Mestra M, Milicic D, Nicolau JC, Ochsorn M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motto M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA; AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;395:1895–1904.

10. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Tacy C, Young JB. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol 2008;102:1524–1529.

11. Savarese G, Vasko P, Jonsson A, Edner M, Dahlstrom U, Lund LH. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Ups J Med Sci 2019;124:65–69.

12. Jankowska EA, Rozenrot N, Widowska A, Nowak J, Hartmann C, Ponikowa B, Borodulin-Nadzieja L, Basinska W, Polonski L, Filipatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872–1880.

13. von Haehling S, Gremmller U, Krumm M, Mibach F, Schoen N, Taggeselle J, Dahm JB, Angermann CE. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP Registry. Clin Res Cardiol 2017;106:416–443.

14. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816–829.

15. Wiesenberger H, Pfister O, Hochadel M, Michel S, Bruder O, Rempiss BA, Maeder O, Remppis BA, Maeder O. Ferric carboxymaltose for iron deficiency and heart failure. N Engl J Med 2010;363:529–539.

16. Savarese G, Lund LH, Dahlstrom U, Stromberg A. Nurse-led heart failure clinics in patients with heart failure are associated with reduced mortality but not heart failure hospitalization. J Am Heart Assoc 2019;8:e011737.

17. Seferovic PM, Vardas P, Jankowska EA, Maggioni AF, Timmis A, Milinkovic J, Polonova M, Gale CP, Lund LH, Lopatin Y, Lainscak M, Savarese G, Huculei R, Kuzakiewicz D, Coats AJ. National Heart Failure Societies of the ESC member countries. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021:239:906–914.

18. Yeo TJ, Yeo PS, Ching-Chiew Wong R, Ong HY, Leong KT, Jaffe-Folly F, Sim D, Santharinikeethan R, Lim SL, M Y Chan M, Chai P, Low AF, Ling LH, Ng TP, Richards AM, Lam CS. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail 2014;16:1125–1132.

19. Kurz K, Lanzar L, Seiffert M, Kocher F, Poldi G, Weiss G. Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. ESC Heart Fail 2020;7:1880–1890.

20. Cournie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart 2002;87:377–378.

21. Ezekwizu JA, McAlister FA, Armstrong PW. Anaemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223–225.

22. Elser N, Jankowska EA, Ponikowski P, Lainscak M, Elser S, Sluzak V, Steinbeck L, Kubo J, Belfanti T, Scherbakov N, Valenlto M, Sandek A, Doehner W, Springer J, Anker SD, von Haehling S. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Agravating Heart Failure. Int J Cardiol 2016;205:6–12.

23. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659–663.

24. Okonko DO, Mandal AK, Missouri CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anaemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241–1251.

25. Campodonico J, Nicolii F, Motta I, Migne De Amicis M, Bonami A, Cappellini M, Agostini P. Prognostic role of transferrin saturation in heart failure patients. Eur J Prev Cardiol 2021 Feb 23:zwa112. https://doi.org/10.1093/ejpc/zwa112 [Epub ahead of print].

26. Moliner P, Enjuanes C, Tajes M, Gainoz-Achirich M, Lupon J, Garay A, Jimeinez-Marrero S, Yun S, Farre N, Cludelles M, Diez C, Gonzalez-Costello J, Comin-Colet J. Association between norepinephrine levels and abnormal iron status in patients with chronic heart failure: is iron deficiency more than a comorbidity? J Am Heart Assoc 2019;8:e010887.

27. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filipatos GS, Fonarow GC, Givertz MM, Hollowell SM, Lindefeldt J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2012 ACCF/AHA/ACP/HFS guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017;69:776–803.

28. McEwan P, Ponikowski P, Davis JA, Rosano G, Coats AJ, Dorigotti F, O’Sullivan D, Ramirez de Arellano A, Jankowska EA. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilizing AFFIRM-AHF. Eur J Heart Fail 2021 Jun 30. https://doi.org/10.1002/ejhf.2270 [Epub ahead of print].

29. Komajda M, Pollat F, Swedberg K, Cleland J, Aguir J, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Koreswijk J, Madeira HC, Moiseyev SV, Preda I, Widimsky J, Freemarne N, Eastaugh J, Halson J. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey Programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464–474.

30. Lund LH, Braunischweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail 2017;19:1270–1279.

31. Savarese G, Carraro JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, Lund LH. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2018;20:1326–1334.

32. Lund LH, Carraro J, Farahmand B, Henriksson KM, Jonsson A, Jernberg T, Dahlstrom U. Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study. Eur J Heart Fail 2017 Sep;19:1107–1116.

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.